Ranbaxy ponies up $50M to resolve overcharging accusations; Merck settles Medicaid fraud claims;

@FiercePharma: Top-read in FiercePharmaMarketing Weds: World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Article | Follow @FiercePharma

@EricPFierce: Remember when FDA asked heparin makers to test APIs for OCSC? This warning letter to a Chinese co. is why. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Have you seen FP's latest report? The top 10 most expensive drugs of 2013. Feature | Follow @CarlyHFierce

> Ranbaxy Laboratories says it will pay $50 million to resolve accusations of overcharging for Medicaid drugs in Texas; the company admits no wrongdoing. Report

> Merck ($MRK) has settled claims of off-label marketing and overpricing Medicaid drugs. Report

> Baxter's ($BAX) Q3 profit dropped on costs tied to its planned biopharma spinoff. Report (sub. req.)

Medical Device News

@FierceMedDev: Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Advisory board recommends that Arkansas Medicaid cut restrictions on $VRTX's cystic-fibrosis drug Kalydeco. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. FierceDrugDelivery article | Follow @MichaelGFierce

> Agilent axes 300 employees to focus on applied markets and diagnostics businesses. More

> Wearable sensor shown effective in preventing bedsores. Story

> Medtronic scores victory in ongoing patent war with Mirowski. Article

Biotech News

@FierceBiotech: InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs. News | Follow @FierceBiotech

@JohnCFierce: Well that tax inversion business was a lot of fun--I wonder what the next big biopharma M&A trend will be. More | Follow @JohnCFierce

@DamianFierce: IPF drugs from $ITMN and Boehringer Ingelheim win FDA approvals at the same time. | Follow @DamianFierce

@EmilyMFierce: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More from FierceVaccines | Follow @EmilyMFierce

> AstraZeneca deepens its Cambridge ties with hopes for Alzheimer's and cancer. Story

> J&J adds an $817M cancer drug pact with ambitious Aduro. Article

> Moderna teams up with Karolinska to flesh out its mRNA promise. Item

Vaccines News

> Sanofi inks pact with Immune Design to boost herpes vax effort. Story

> Bexsero could be cost-effective for England, model says--but not at Novartis' price. Report

> Sanofi, Selecta join hands in diabetes vaccine push. Article

> NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More

> Sanofi takes rotavirus vax into Phase III with eye on Indian market. Story

Pharma Manufacturing News

> FDA bans maker of suspect Chinese heparin. More

> Court orders Indian drugmaker to destroy $11M worth of unapproved drugs. Story

> FDA cites animal drug compounder for selling copies of Novartis' Capstar. Item

> Italy's Cosmos to build manufacturing plant in Ireland. News

> Abbott opens third nutrition plant this year. Article

And Finally... The benefits of Novartis' ($NVS) psoriasis candidate secukinumab outweigh its risks, FDA staffers say. More

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.